Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The impact of physical exercise on neuromuscular function in Myasthenia gravis patients: A single-subject design study.

Westerberg E, Molin CJ, Spörndly Nees S, Widenfalk J, Punga AR.

Medicine (Baltimore). 2018 Aug;97(31):e11510. doi: 10.1097/MD.0000000000011510.

2.

Advances in autoimmune myasthenia gravis management.

Wang S, Breskovska I, Gandhy S, Punga AR, Guptill JT, Kaminski HJ.

Expert Rev Neurother. 2018 Jul;18(7):573-588. doi: 10.1080/14737175.2018.1491310. Epub 2018 Jul 4.

PMID:
29932785
3.

Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.

Sabre L, Maddison P, Sadalage G, Ambrose PA, Punga AR.

J Neuroimmunol. 2018 Aug 15;321:164-170. doi: 10.1016/j.jneuroim.2018.05.003. Epub 2018 May 8.

4.

Reply to "high abnormal rate in the repetitive nerve stimulation test in acute onset myasthenia gravis".

Punga AR, Liik M.

Clin Neurophysiol. 2018 Jun;129(6):1339. doi: 10.1016/j.clinph.2018.03.004. Epub 2018 Mar 23. No abstract available.

PMID:
29625881
5.

Thymectomy lowers the myasthenia gravis biomarker miR-150-5p.

Molin CJ, Sabre L, Weis CA, Punga T, Punga AR.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e450. doi: 10.1212/NXI.0000000000000450. eCollection 2018 May.

6.

Circulating microRNAs as potential biomarkers in myasthenia gravis patients.

Punga AR, Punga T.

Ann N Y Acad Sci. 2018 Jan;1412(1):33-40. doi: 10.1111/nyas.13510. Epub 2017 Nov 10. Review.

PMID:
29125182
7.

Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.

Alimohammadi M, Punga AR.

Toxins (Basel). 2017 Oct 30;9(11). pii: E352. doi: 10.3390/toxins9110352. Review.

8.

Diagnostic Utility of Repetitive Nerve Stimulation in a Large Cohort of Patients With Myasthenia Gravis.

Amandusson Å, Elf K, Grindlund ME, Punga AR.

J Clin Neurophysiol. 2017 Sep;34(5):400-407. doi: 10.1097/WNP.0000000000000398.

PMID:
28872522
9.

Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries.

Sabre L, Westerberg E, Liik M, Punga AR.

Brain Behav. 2017 Mar 1;7(4):e00653. doi: 10.1002/brb3.653. eCollection 2017 Apr.

10.

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients.

Molin CJ, Westerberg E, Punga AR.

Sci Rep. 2017 Jan 3;7:39716. doi: 10.1038/srep39716.

11.

Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study.

Westerberg E, Molin CJ, Lindblad I, Emtner M, Punga AR.

Muscle Nerve. 2017 Aug;56(2):207-214. doi: 10.1002/mus.25493. Epub 2017 Apr 2.

PMID:
27935072
12.

Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized Myasthenia Gravis.

Liik M, Punga AR.

Clin Neurophysiol. 2016 Nov;127(11):3480-3484. doi: 10.1016/j.clinph.2016.09.012. Epub 2016 Oct 3.

PMID:
27744133
13.

A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines.

Punga AR, Alimohammadi M, Fagrell D, Nyberg F, Rees D, Wong C.

Dermatol Surg. 2016 Aug;42(8):967-76. doi: 10.1097/DSS.0000000000000805.

14.

Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.

Punga T, Bartoccioni E, Lewandowska M, Damato V, Evoli A, Punga AR.

J Neuroimmunol. 2016 Mar 15;292:21-6. doi: 10.1016/j.jneuroim.2016.01.003. Epub 2016 Jan 7.

15.

Compound Motor Action Potential: Electrophysiological Marker for Muscle Training.

Molin CJ, Punga AR.

J Clin Neurophysiol. 2016 Aug;33(4):340-5. doi: 10.1097/WNP.0000000000000252.

PMID:
26744834
16.

Low vitamin D levels in healthy controls and patients with autoimmune neuromuscular disorders in Greece.

Chroni E, Dimisianos N, Punga AR.

Acta Neurol Belg. 2016 Mar;116(1):57-63. doi: 10.1007/s13760-015-0512-2. Epub 2015 Jul 17.

PMID:
26183131
17.

Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients.

Punga AR, Andersson M, Alimohammadi M, Punga T.

J Neurol Sci. 2015 Sep 15;356(1-2):90-6. doi: 10.1016/j.jns.2015.06.019. Epub 2015 Jun 14.

18.

Regional diffusion of botulinum toxin in facial muscles: a randomised double-blind study and a consideration for clinical studies with split-face design.

Punga AR, Eriksson A, Alimohammadi M.

Acta Derm Venereol. 2015 Nov;95(8):948-51. doi: 10.2340/00015555-2093.

19.

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Phillips WD, Christadoss P, Losen M, Punga AR, Shigemoto K, Verschuuren J, Vincent A.

Exp Neurol. 2015 Aug;270:29-40. doi: 10.1016/j.expneurol.2014.12.013. Epub 2014 Dec 24.

PMID:
25542979
20.

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker.

Punga T, Le Panse R, Andersson M, Truffault F, Berrih-Aknin S, Punga AR.

Ann Clin Transl Neurol. 2014 Jan;1(1):49-58. doi: 10.1002/acn3.24. Epub 2013 Dec 30.

21.

Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies.

Elf K, Askmark H, Nygren I, Punga AR.

J Neurol Sci. 2014 Oct 15;345(1-2):184-8. doi: 10.1016/j.jns.2014.07.040. Epub 2014 Jul 26.

PMID:
25115500
22.
23.

Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG).

Chauhan M, Punga T, Punga AR.

Neurosci Res. 2013 Sep-Oct;77(1-2):102-9. doi: 10.1016/j.neures.2013.07.008. Epub 2013 Aug 7.

PMID:
23933211
24.

β-glucans reduce LDL cholesterol in patients with myasthenia gravis.

Haggård L, Andersson M, Punga AR.

Eur J Clin Nutr. 2013 Feb;67(2):226-7. doi: 10.1038/ejcn.2012.191. Epub 2012 Nov 28.

PMID:
23187951
25.

Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS.

Meinen S, Lin S, Rüegg MA, Punga AR.

PLoS One. 2012;7(8):e44148. doi: 10.1371/journal.pone.0044148. Epub 2012 Aug 28.

26.

Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study.

Askmark H, Haggård L, Nygren I, Punga AR.

Eur J Neurol. 2012 Dec;19(12):1554-60. doi: 10.1111/j.1468-1331.2012.03773.x. Epub 2012 Jun 4.

PMID:
22672742
27.

Usefulness of assessing repeater F-waves in routine studies.

Chroni E, Tendero IS, Punga AR, Stålberg E.

Muscle Nerve. 2012 Apr;45(4):477-85. doi: 10.1002/mus.22333.

PMID:
22431079
28.

Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases.

Punga AR, Ruegg MA.

Curr Opin Pharmacol. 2012 Jun;12(3):340-6. doi: 10.1016/j.coph.2012.02.002. Epub 2012 Feb 23. Review.

PMID:
22365504
29.

Neurophysiological characteristics of MuSK antibody positive myasthenia gravis mice: focal denervation and hypersensitivity to acetylcholinesterase inhibitors.

Chroni E, Punga AR.

J Neurol Sci. 2012 May 15;316(1-2):150-7. doi: 10.1016/j.jns.2011.12.016. Epub 2012 Jan 16.

PMID:
22251934
30.

Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice.

Punga AR, Lin S, Oliveri F, Meinen S, Rüegg MA.

Exp Neurol. 2011 Aug;230(2):207-17. doi: 10.1016/j.expneurol.2011.04.018. Epub 2011 Apr 30.

PMID:
21565192
31.

MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity.

Punga AR, Maj M, Lin S, Meinen S, Rüegg MA.

Eur J Neurosci. 2011 Mar;33(5):890-8. doi: 10.1111/j.1460-9568.2010.07569.x. Epub 2011 Jan 24.

PMID:
21255125
32.

Acetylcholinesterase inhibitors in MG: to be or not to be?

Punga AR, Stålberg E.

Muscle Nerve. 2009 Jun;39(6):724-8. doi: 10.1002/mus.21319. Review.

PMID:
19260048
33.

Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate.

Punga AR, Nygren I, Askmark H, Stålberg EV.

Acta Neurol Scand. 2009 Mar;119(3):207-11. doi: 10.1111/j.1600-0404.2008.01082.x. Epub 2008 Aug 5.

PMID:
18684214
34.

Indication of peripheral nerve hyperexcitability in adult-onset subacute sclerosing panencephalitis (SSPE).

Schreurs A, Stålberg EV, Punga AR.

Neurol Sci. 2008 Apr;29(2):121-4. doi: 10.1007/s10072-008-0872-y. Epub 2008 May 16.

PMID:
18483711
35.
36.

Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.

Punga AR, Flink R, Askmark H, Stålberg EV.

Muscle Nerve. 2006 Jul;34(1):111-5.

PMID:
16453324

Supplemental Content

Loading ...
Support Center